Medicinal Chemistry of Anticancer Drugs

In recent decades, combating cancer and preventing its onset have become major priorities for healthcare systems worldwide. Significant progress has been made in both treating various types of cancer and improving survival rates, thanks to advancements in therapeutic methods and the development of effective antitumor drugs. Today, the discovery and creation of anticancer medications are key areas of focus for pharmaceutical companies, research institutions, and both government and non-government organizations globally. Remarkable strides have been made in identifying and developing drugs that can target cancer cells. Numerous chemical compounds—whether synthetic or derived from natural sources—have been tested for their potential to fight cancer. However, despite these efforts, the pace of discovering truly successful anticancer agents remains slow. In fact, the failure rate for new cancer drugs is alarmingly high, with approximately 95% of drug candidates not making it past clinical trials, a much steeper decline compared to other medical fields. The costs involved in developing these drugs are also significant. It can take millions of dollars and many years of research to bring a promising anticancer drug to market. Despite these challenges, the relentless pursuit of effective cancer therapies continues, offering hope for better treatments and a future where cancer can be managed more successfully. Developing anticancer drugs is a complex and time-consuming process. After a drug candidate is identified, it must undergo extensive toxicological testing and pass through three phases of clinical trials before it can be approved for use. This review explores several crucial aspects of anticancer drug research, including the discovery, development, marketing, and the high costs associated with their therapeutic use over the past decade. It also discusses the approval process by three key regulatory bodies: the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).The review highlights the advances in cancer treatment that have been explored in the last ten years, focusing on the identification of specific biochemical characteristics of cancer cells that can be targeted more effectively. These discoveries are key to developing therapies that selectively attack tumor cells, reducing damage to healthy tissue. Market research shows that the global anticancer drug market has grown at a remarkable pace. However, the rise of counterfeit drugs, particularly those sold online, has created significant challenges for both pharmaceutical companies and the safety of cancer patients. In 2012, the total sales of anticancer drugs worldwide reached $80 billion, with these drugs leading the global market in terms of spending by therapeutic class. This highlights the immense financial stakes and the increasing demand for effective cancer treatments.